TG6002 / Transgene, Tasly 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   33 News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TG6002 / Transgene, Tasly
NCT04194034 / 2018-004103-39: Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Terminated
2a
15
Europe
TG6002, Flucytosine (5-FC)
Transgene
Colorectal Neoplasms
02/23
02/23
NCT04226066: Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Recruiting
1/2
69
RoW
T601, T601+5-FC
Tasly Tianjin Biopharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
05/21
05/22
NCT03724071 / 2018-000039-28: Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Terminated
1/2
51
Europe
TG6002, Flucytosine (5-FC, Ancotil)
Transgene
Colorectal Neoplasm, Digestive System Neoplasm
02/23
02/23

Download Options